Hologic (HOLX) late Wednesday reported fiscal Q1 non-GAAP earnings of $1.03 per diluted share, up from $0.98 a year earlier.
Analysts polled by FactSet, on average, expected $1.02.
Net sales for the quarter ended Dec. 28 were $1.02 billion compared with $1.01 billion a year earlier. Analysts expected $1.02 billion.
For Q2, the health care company is looking for non-GAAP EPS of $1.00 to $1.03 on revenue of $995 million to $1.01 billion. Analysts are expecting $1.04 and $1.03 billion, respectively.
For 2025, Hologic is now projecting non-GAAP EPS of $4.25 to $4.35 compared with the analyst consensus expecting $4.26.
It cut projected revenue for 2025 to $4.05 billion to $4.1 billion from its prior range expecting $4.15 billion to $4.2 billion. The analyst consensus is expecting $4.16 billion.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。